Denosumab in early-stage breast cancer - Authors' reply

Lancet Oncol. 2019 May;20(5):236. doi: 10.1016/S1470-2045(19)30228-1.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Bone Density Conservation Agents*
  • Breast Neoplasms*
  • Denosumab
  • Disease-Free Survival
  • Double-Blind Method
  • Humans
  • Postmenopause

Substances

  • Bone Density Conservation Agents
  • Denosumab